Abstract
MicroRNAs (miRNAs) are a class of post-transcriptional gene expression modulators. In the past two decades, over 1500 human miRNAs were discovered. These small non-coding RNAs regulate various biological processes, including cell growth, proliferation, differentiation, and cell death. Thus, miRNAs have been proposed as new therapeutical agents in different multifactorial diseases such as cancer. Since miRNAs therapies represent a great promise, many research studies have been focused on the development of delivery strategies to overcome miRNAs biopharmaceutical issues. Lipid delivery systems are undoubtedly the non-viral carriers most largely investigated due to their biocompatibility, biodegradability, easy production, low toxicity and immunogenicity, possibility to easily modify the carriers for targeting strategies. In this mini-review we provide a rapid and updated overview on the lipid delivery system currently used to deliver miRNAs, pointing out the progresses achieved in the optimization of these nanovectors, which led up to the first clinical trial.
Keywords: microRNAs; miRNA delivery, nanocarriers; lipid-based delivery systems; liposomes, SNALPs, solid lipid nanoparticles, nanoemulsions, drug targeting.
Current Pharmaceutical Biotechnology
Title:Lipid Nanoparticles to Deliver miRNA in Cancer
Volume: 17 Issue: 8
Author(s): Virginia Campani, Giuseppe De Rosa, Gabriella Misso, Mayra R. Zarone and Anna Grimaldi
Affiliation:
Keywords: microRNAs; miRNA delivery, nanocarriers; lipid-based delivery systems; liposomes, SNALPs, solid lipid nanoparticles, nanoemulsions, drug targeting.
Abstract: MicroRNAs (miRNAs) are a class of post-transcriptional gene expression modulators. In the past two decades, over 1500 human miRNAs were discovered. These small non-coding RNAs regulate various biological processes, including cell growth, proliferation, differentiation, and cell death. Thus, miRNAs have been proposed as new therapeutical agents in different multifactorial diseases such as cancer. Since miRNAs therapies represent a great promise, many research studies have been focused on the development of delivery strategies to overcome miRNAs biopharmaceutical issues. Lipid delivery systems are undoubtedly the non-viral carriers most largely investigated due to their biocompatibility, biodegradability, easy production, low toxicity and immunogenicity, possibility to easily modify the carriers for targeting strategies. In this mini-review we provide a rapid and updated overview on the lipid delivery system currently used to deliver miRNAs, pointing out the progresses achieved in the optimization of these nanovectors, which led up to the first clinical trial.
Export Options
About this article
Cite this article as:
Campani Virginia, De Rosa Giuseppe, Misso Gabriella, R. Zarone Mayra and Grimaldi Anna, Lipid Nanoparticles to Deliver miRNA in Cancer, Current Pharmaceutical Biotechnology 2016; 17 (8) . https://dx.doi.org/10.2174/138920101708160517234941
DOI https://dx.doi.org/10.2174/138920101708160517234941 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Management of Alcoholic Liver Disease
Current Drug Abuse Reviews Targeting Cancer Stem Cells: Promises and Challenges
Anti-Cancer Agents in Medicinal Chemistry Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Cyclodepsipeptides - Potential Drugs and Lead Compounds in the Drug Development Process
Current Medicinal Chemistry A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry Marine Natural Products with High Anticancer Activities
Current Medicinal Chemistry Non-histone Methylation of SET7/9 and its Biological Functions
Recent Patents on Anti-Cancer Drug Discovery Hemolytic Uremic Syndrome in Children
Current Pediatric Reviews Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment
Current Cancer Drug Targets miR-375 Inhibits the Proliferation, Migration and Invasion of Esophageal Squamous Cell Carcinoma by Targeting XPR1
Current Gene Therapy The Role of Stem Cells in Muscular Dystrophies
Current Gene Therapy A Combination of Two Antioxidants (An SOD Mimic and Ascorbate) Produces a Pro-Oxidative Effect Forcing Escherichia coli to Adapt Via Induction of oxyR Regulon
Anti-Cancer Agents in Medicinal Chemistry Drug Targeting Approaches and Use of Drug Delivery Systems in Management of Cancer
Current Pharmaceutical Design Computer-Aided Drug Design Methodologies Toward the Design of Anti-Hepatitis C Agents
Current Topics in Medicinal Chemistry Pyrimidine Nucleosides in Molecular PET Imaging of Tumor Proliferation
Current Medicinal Chemistry Anti-Tumor Effects of Osthole on Different Malignant Tissues: A Review of Molecular Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Dietary Nitrite in Nitric Oxide Biology: A Redox Interplay with Implications for Pathophysiology and Therapeutics
Current Drug Targets Src Family Kinases as Regulators of Angiogenesis: Therapeutic Implications
Current Cancer Therapy Reviews Calpain-Associated Proteolytic Regulation of the Stromal Microenvironment in Cancer
Current Pharmaceutical Design Pharmacogenomics of Xenobiotic Metabolizing Enzymes in South American Populations
Current Pharmacogenomics